Literature DB >> 11406189

Pharmacological effects of AMPA receptor potentiators LY392098 and LY404187 on rat neuronal AMPA receptors in vitro.

M Gates1, A Ogden, D Bleakman.   

Abstract

The present study describes the pharmacological activity of two novel positive allosteric modulators at AMPA receptors in acutely isolated rat cerebellar Purkinje neurons and cultured rat hippocampal neurons. Currents elicited by application of glutamate (100 microM) to isolated cerebellar Purkinje neurons were potentiated by LY392098, LY404187, cyclothiazide, CX516 and aniracetam. The rank order of potency was LY404187> LY392098> cyclothiazide > CX516> aniracetam. LY392098 displayed a higher maximal efficacy than the other compounds examined. AMPA-activated inward currents in cultured rat hippocampal neurons were potentiated by LY392098, LY404187 and cyclothiazide in a reversible and concentration-dependent manner although considerable heterogeneity in the magnitude of response from cell to cell was observed. LY392098 was ineffective in potentiating AMPA receptor responses when dialyzed via the intracellular solution. The selectivity profiles of the two novel AMPA receptor potentiators were examined. LY392098 or LY404187 had minimal activity on NMDA receptor responses, on voltage-gated calcium channel currents in cultured hippocampal neurons and on GluR5 kainate receptor currents in acutely isolated rat dorsal root ganglion neurons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406189     DOI: 10.1016/s0028-3908(01)00040-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders.

Authors:  Stefano Marenco; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 2.  Retour aux sources: defining the structural basis of glutamate receptor activation.

Authors:  G Brent Dawe; Mark R Aurousseau; Bryan A Daniels; Derek Bowie
Journal:  J Physiol       Date:  2014-10-21       Impact factor: 5.182

3.  Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging.

Authors:  Nicholas Jones; Michael J O'Neill; Mark Tricklebank; Vincenzo Libri; Steve C R Williams
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

Review 4.  Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data.

Authors:  Mark D Black
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

5.  Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease.

Authors:  Paula T Trzepacz; Jeffrey Cummings; Thomas Konechnik; Tammy D Forrester; Curtis Chang; Ellen B Dennehy; Brian A Willis; Catherine Shuler; Linda B Tabas; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2012-12-21       Impact factor: 3.878

6.  TAK-137, an AMPA-R potentiator with little agonistic effect, has a wide therapeutic window.

Authors:  Akiyoshi Kunugi; Maiko Tanaka; Atsushi Suzuki; Yasukazu Tajima; Noriko Suzuki; Motohisa Suzuki; Shinji Nakamura; Haruhiko Kuno; Akihiro Yokota; Satoshi Sogabe; Yohei Kosugi; Yasuyuki Awasaki; Tomohiro Kaku; Haruhide Kimura
Journal:  Neuropsychopharmacology       Date:  2018-09-12       Impact factor: 7.853

7.  Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors.

Authors:  Sylvie Bretin; Caroline Louis; Laure Seguin; Stéphanie Wagner; Jean-Yves Thomas; Sylvie Challal; Nathalie Rogez; Karine Albinet; Fabrice Iop; Nadège Villain; Sonia Bertrand; Ali Krazem; Daniel Bérachochéa; Stéphanie Billiald; Charles Tordjman; Alex Cordi; Daniel Bertrand; Pierre Lestage; Laurence Danober
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.